Marshall Wace’s LB Pharmaceuticals LBRX Stock Holding History

Marshall Wace’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-18,014	Closed	-$401K	–	3791
2025 Q4	$401K	Sell	18,014 -237,512	-93%	-$4.15M	﹤0.01%	2335
2025 Q3	$4.03M	Buy	+255,526	New	+$4.05M	﹤0.01%	1273

Other funds holding LBRX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Marshall Wace's LBRX Position: Q1 2026 in Review

Marshall Wace sold out of LB Pharmaceuticals (LBRX) in Q1 2026, closing a stake of 18,014 shares — an estimated $401K sold.

Marshall Wace first reported a position in LBRX in Q3 2025 and held it in 2 quarters. The position peaked at $4.03M in Q3 2025. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

Marshall Wace reported no remaining LB Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Marshall Wace sold 18,014 LB Pharmaceuticals shares in Q1 2026, an estimated $401K.
Marshall Wace first reported a position in LB Pharmaceuticals in Q3 2025 and held it in 2 quarters.
Marshall Wace's LB Pharmaceuticals position peaked at $4.03M in Q3 2025.
77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.